![]() | ![]() |
Formats:
|
||||||||||||||||||
BMP-binding modules in chordin: a model for signalling regulation in the extracellular space Howard Hughes Medical Institute and Department of Biological Chemistry, University of California, Los Angeles, CA 90095−1662, USA *These authors contributed equally to the work ‡Present address: Istituto di Istologia ed Embriologia, Universitá di Padova, 35100 Padova, Italy §Author for correspondence (fax: 310−206−2008) The publisher's final edited version of this article is available free at Development. See other articles in PMC that cite the published article.SUMMARY A number of genetic and molecular studies have implicated Chordin in the regulation of dorsoventral patterning during gastrulation. Chordin, a BMP antagonist of 120 kDa, contains four small (about 70 amino acids each) cysteine-rich domains (CRs) of unknown function. In this study, we show that the Chordin CRs define a novel protein module for the binding and regulation of BMPs. The biological activity of Chordin resides in the CRs, especially in CR1 and CR3, which have dorsalizing activity in Xenopus embryo assays and bind BMP4 with dissociation constants in the nanomolar range. The activity of individual CRs, however, is 5- to 10-fold lower than that of full-length Chordin. These results shed light on the molecular mechanism by which Chordin/BMP complexes are regulated by the metalloprotease Xolloid, which cleaves in the vicinity of CR1 and CR3 and would release CR/BMP complexes with lower anti-BMP activity than intact Chordin. CR domains are found in other extracellular proteins such as procollagens. Full-length Xenopus procollagen IIA mRNA has dorsalizing activity in embryo microinjection assays and the CR domain is required for this activity. Similarly, a C. elegans cDNA containing five CR domains induces secondary axes in injected Xenopus embryos. These results suggest that CR modules may function in a number of extracellular proteins to regulate growth factor signalling. Keywords: BMP, Chordin, Collagen, TGFβ, Spemann organizer INTRODUCTION Recent work suggests that cell signaling in embryos is modulated by secreted proteins that bind to and inhibit growth factors in the extracellular space (Harland and Gerhart, 1997; Nieto et al., 1999). In Xenopus, dorsoventral patterning is regulated by the antagonistic interaction between Chordin and Bone Morphogenetic Proteins (BMPs). Chordin, a protein of 120 kDa secreted by Spemann's organizer (De Robertis and Sasai, 1996) binds to ventral BMPs in the extracellular space, preventing the interaction of BMPs with their receptors (Piccolo et al., 1996). The region in Chordin to which BMPs bind has not yet been identified. This model of dorsoventral patterning has received strong support from genetic analyses in model organisms. In zebrafish, chordino, a mutant encoding a null allele of chordin, has a reduction of dorsal structures in ectoderm and mesoderm (Schulte-Merker et al., 1997) and genetically interacts with the dorsalizing mutant swirl, which is a BMP2 loss-of-function allele (Kishimoto et al., 1997). Double chordino; swirl loss-of-function mutants display a swirl dorsalized phenotype, suggesting that the sole function of Chordin is to inhibit BMP signals (Hammerschmidt et al., 1996). In Drosophila, short-gastrulation (sog), a chordin homologue (François and Bier, 1995; Holley et al., 1995), antagonizes decapentaplegic (dpp) and screw, which function as dorsoventral morphogens in the Drosophila embryo (Ferguson and Anderson, 1992; Neul and Ferguson, 1998; Nguyen et al., 1998) and are functionally homologous to vertebrate BMPs (Padgett et al., 1993; Holley et al., 1995). As is the case for swirl and chordino, dpp and screw are epistatic to sog in double mutants (Biehs et al., 1996; Holley et al., 1996; Neul and Ferguson, 1998), indicating that Sog is a dedicated antagonist of BMP signals. Xolloid, an extracellular zinc metalloproteinase, cleaves Chordin at two specific sites (Piccolo et al., 1997). Cleavage of inactive Chordin/BMP complexes results in the reactivation of BMPs, which are then able to signal and ventralize Xenopus explants, providing a paradigm for how a protease can reverse an inhibitory interaction in the extracellular space (Piccolo et al., 1997). These results are in agreement with genetic studies in Drosophila, in which the product of tolloid, a Xolloid homologue, enhances the activity of Dpp (Ferguson and Anderson, 1992; Ashe and Levine, 1999) and can cleave Sog (Marqués et al., 1997). In zebrafish, loss-of-function mutations in a tolloid homologue, mini-fin, cause excessive dorsal tissue to form in a manner consistent with an increased activity of Chordin (Connors et al., 1999). Despite intense biological interest, the molecular mechanism by which Chordin/BMP complexes are regulated by Tolloid proteases, including the properties of the cleavage products, remains unknown. Chordin, like Sog in Drosophila, contains four cysteine-rich repeats (CRs) that share similarities, particularly in the spacing of their 10 cysteines, with many extracellular matrix (ECM) proteins, including fibrillar procollagens, thrombospondin and von Willebrand factor (François et al., 1994; Sasai et al., 1994). In the case of fibrillar procollagens I, II, III and V, which are the major components of the ECM of skin, bones and cartilage (Scriver et al., 1995), the CR domain is present in the NH2-propeptide. It has recently been shown that BMP2 and TGFβ1 can bind to the procollagen IIA CR domain (Zhu et al., 1999), although no biological activity was demonstrated. In the present study, we show that the biological activity of Chordin resides in the CRs, particularly in CR1 and CR3. However, we also show that these domains have BMP binding and biological activities that are 5−10 times lower than those of full-length Chordin. We propose that Xolloid inactivates Chordin by the production of fragments which, although still retaining binding activity, have less affinity for BMP than full-length Chordin. Finally, we show that type IIA procollagen containing a CR domain has dorsalizing activity in Xenopus assays. Therefore, procollagen IIA, which is expressed in the notochord and dorsal somites, could function as a regulatory molecule during dorsal development in vertebrates. Taken together, the results suggest that the Chordin CRs define a modular BMP-binding domain that may provide a paradigm for understanding the function of a number of extracellular proteins containing similar domains. MATERIALS AND METHODS Expression constructs and synthetic mRNA preparation Full-length chordin (accession number AF096276) was cloned by low-stringency screening of a mouse 6.5 day embryo cDNA library prepared in this laboratory by Drs M. Blum and J. C. Izpisúa-Belmonte. To construct the library, cDNA was directionally cloned into the SacI-EcoRI and HindIII sites of the λSHlox-1 vector (Novagen). The sequence of mouse Chordin has been reported by Pappano et al. (1998) and by Bachiller et al. (2000). The full-length cDNA was divided into three parts by making use of conveniently located internal restriction sites BamHI and BglII. Each fragment was cloned into the pCS2 expression vector (Lee et al., 1995) carrying a mouse Chordin signal peptide without epitope tag. PCR fragments of individual CRs (with 20 amino acids of flanking sequence at each end and SacI and XbaI cloning sites) were synthesized using the full-length mouse chordin cDNA as template and cloned into a pCS2 expression construct containing the mouse Chordin signal peptide and putative signal peptidase cleavage site (amino acids 1−32), followed by a Myc epitope tag (EQKLISEEDL) and a SacI cloning site. The primers used to amplify the individual repeats were:
The full-length Xenopus procollagen IIA cDNA was excised with EcoRI from a pUC18 vector (a kind gift of Dr Francesco Ramirez) and ligated to pCS2. For the type IIA procollagen CR construct a PCR fragment (440 bp) containing the CR domain in a SacI-XbaI fragment was cloned into the same pCS2 expression vector used for the mouse Chordin CR domains and designated pCS2-myc-Coll II-CR. The primers used to amplify the collagen CR were: F5’-CGATGCCAAGATGAAGAAGAT-3’, R5’-TTCTCCTCTAGATCCTTGTTCACC-3’. To prepare a collagen II construct mimicking the type IIB transcript lacking the CR (Ryan and Sandell, 1990), we used pCS2-myc-Coll II-CR as a template for deletion of amino acids D34 to S102 in Xenopus collagen II (Su et al., 1991) by a PCR procedure. The amplified fragment was digested with EcoRI and XbaI and cloned in a three-fragment ligation with a 4000 bp XbaI-StuI fragment of Xenopus collagen II and pCS2 vector cut with EcoI and StuI, to generate pCS2-myc-procollagen IIB. A similar ligation was carried out with the original pCS2-myc-Coll-CR EcoRI-XbaI fragment to generate pCS2-myc-procollagen IIA. This construct had the same activity as pCS2-procollagen IIA lacking the myc-tag in embryo injections and was used as the control in the experiments using myc-procollagen IIB mRNA. Both myc-tagged collagen constructs produced stable secreted proteins of the expected length when transfected into 293T cells. To prepare C. elegans CAA04886 expression vector the full-length cDNA, EST yk227e2, obtained from Dr Yuji Kohara (National Institute of Genetics, Japan) was subcloned into pCS2. Synthetic mRNAs for microinjection was prepared in all cases from pCS2-based vectors linearized with NotI and transcribed with SP6 Polymerase using the Message Machine kit (Ambion). For in situ collagen II hybridizations, we used a 1200 nucleotide probe from the 3’ region (Su et al., 1991), generated by linearizing pCS2-AS-Coll II with XhoI and transcribing with SP6 RNA polymerase. The Xenopus chordin probe was as described (Sasai et al., 1994). Protein expression and quantitation Human 293T cells were transfected at 70% confluence (Piccolo et al., 1997) with Myc-tagged CR1, CR2, CR3, CR4 or full-length mouse Chordin in pCS2 (15 μg of DNA per 10 cm Petri dish) in DMEM-10% fetal calf serum. 24 hours after transfection, a subconfluent cell monolayer was washed three times with Hank's balanced salt solution and cultured in serum-free Iscove's medium for 48 hours. Proteins secreted by 293T cells transfected with pCS2 without insert and cultured in the same way were used as a negative control throughout this study. The conditioned media were concentrated and the buffer exchanged to CMFM by Centriplus-30 (Amicon). To this end, samples were first concentrated 10 times and then diluted 10 times with CMFM; this procedure was repeated twice (Piccolo et al., 1997). Aliquots were snap frozen and stored at −80°C. Protein was quantitated on western blots using a range of concentrations of a standard protein (Xenopus Myc-Chordin, Piccolo et al., 1996) and an anti-Myc monoclonal antibody (Santa Cruz Biotech). Immunoprecipitation Mouse Chordin and CR proteins were incubated with BMP4 for 3 hours on ice in 100 μl of saline buffer containing 150 mM NaCl, 20 mM Tris-HCl pH 7.5, 1.5 mM CaCl2, 1.5 mM MgCl2, 0.1% Triton X-100, 0.1% Octyglucoside, 0.1% CHAPS, 5% glycerol and 0.1% BSA (IP buffer). A polyclonal anti-Myc antibody (Santa Cruz Biotech, lot no. C028, 5 μl of serum per reaction) was prebound to protein A Sepharose (Pharmacia) and 20 μl of resuspended beads were added to each reaction. In some experiments, a commercial mouse BMPR-IA/Fc fusion protein (R&D Systems) was bound to BMP4 and competed with Chd or CR1 proteins and then bound to protein A Sepharose. After binding at 4°C for 2 hours in an Eppendorf tube with constant mixing, beads were pelleted at 14,000 revs/minute for 1 minute at 4°C, resuspended in precooled 1 ml of IP buffer as above, except for the omission of BSA and washed three times at 4°C (5 minute per wash). To elute BMP/CR complexes, anti-Myc beads were incubated in 20 μl of 1 M NaCl, 0.15% SDS, 10 mM Tris-HCl pH 6.8 for 15 minutes at 37°C. After centrifugation, the supernatants were subjected to SDS gel electrophoresis under reducing conditions and BMP4 was detected with monoclonal antibody as described (Piccolo et al., 1996). Embryological manipulations and RT-PCR analysis Artificial fertilization and mRNA injection into Xenopus embryos were performed as described (Sasai et al., 1994). Ventral marginal zone explants (constituting 60° of the VMZ) from stage 10 embryos were prepared in LCMR (Piccolo et al., 1996), opened with an eyebrow knife, and immediately treated with LCMR containing various protein concentrations of the individual CR domains and of full-length Chordin. After overnight incubation at room temperature, the explants were transferred to 0.4× MMR. Immunostaining with the muscle marker 12−101 was as described (Gont et al., 1996). Expression of marker genes was assayed by RT-PCR at stage 27. The conditions and primer sequences were as described (Sasai et al., 1995; www.lifesci.ucla.edu/hhmi/derobertis/index.html). RESULTS The biological activity of Chordin resides in the cysteine-rich repeats In the course of ongoing targeted mutation studies, mice homozygous for a truncated chordin allele lacking the three C-terminal CRs (CR2−4), but retaining CR1 and most of the inter-repeat region, were found to be viable hypomorphic mutants displaying only minor skeletal defects (D. B., J. Klingensmith, J. Rossant and E. M. D. R., unpublished results). This observation suggested that the chordin gene fragment retained partial biological activity, and provided the initial impetus for analyzing the function of the Chordin CR domains. A full-length mouse chordin cDNA was first subdivided making use of convenient restriction sites. As shown in Fig. 1
Injection of full-length chordin mRNA induces secondary axes and dorsalizes the Xenopus embryo (Sasai et al., 1994), and we used this as our activity assay. Single ventral injections of synthetic mRNAs into Xenopus embryos showed that the inter-repeat region (constituting over half of the total protein) was devoid of activity, whereas the two constructs containing CRs had biological activity; CR1 generated principally embryos with increased dorsoanterior structures and the 3 CRs induced mainly secondary axes (Fig. 1 CR1 or CR3 overexpression dorsalizes Xenopus embryos To explore the function of individual CRs, each repeat was cloned in an expression vector encoding the mouse Chordin signal peptide followed by a Myc epitope-tag (Fig. 1
Embryos injected with CR1 or CR3 mRNA (100 pg) were predominantly dorsalized (Fig. 2A,B The differences in activity observed between CR1/CR3 and CR2/CR4 injections could have been due to differences in translation efficiency of the different constructs. In order to exclude this, conditioned medium from 293T human kidney cells transiently transfected with each one of the Myc-tagged repeats were quantitated and tested in ventral marginal zone (VMZ) assays. VMZs were explanted at early gastrula and incubated in each CR protein preparation at 20 nM. As shown in Fig. 2C CR modules bind BMP4 To investigate whether individual CR domains can bind BMP4 directly, the same protein preparations tested above were used in co-immunoprecipitation assays. Equal concentrations (2 nM) of each CR protein were incubated with 1.5 nM BMP4, immunoprecipitated with anti-Myc polyclonal antibody and the amount of BMP4 bound to each CR was determined on western blots (Piccolo et al., 1996). Whereas all four CRs bound BMP4 to a detectable extent, CR1 and CR3 bound more effectively than CR2 and CR4 (Fig. 2D For a more quantitative analysis of the binding affinity of CR1 and CR3, the immunoprecipitation binding assay was carried out with increasing concentrations of BMP4 (Fig. 3A
Chordin has been shown to preferentially bind BMPs (BMP2 and BMP4), but not other members of TGFβ family such as Activin (Piccolo et al., 1996). To address the issue of the specificity of the interactions with isolated CRs, we competed the BMP4 binding to CR1 with a 10-fold molar excess of BMP2, activin, EGF, IGF and TGFβ1. As shown in Fig. 3B CR1 has less anti-BMP activity than Chordin Since CR1 binds BMP4 with a lower affinity than full-length Chordin, we investigated whether CR1 had less anti-BMP dorsalizing activity than Chordin. VMZ explants were incubated with conditioned medium containing different concentrations of CR1 or Chordin proteins. As shown in Fig. 4A
The lower activity of CR1 compared to full-length chordin was also observed when equimolar amounts of synthetic mRNA were injected into Xenopus embryos. As shown in Fig. 4B In order to determine whether CR1 has lower affinity for BMP4 when compared in parallel to full-length Chordin, an equilibrium binding experiment was performed. Mouse BMPR/Fc fusion protein was bound to BMP4 in the absence or presence of increasing amounts of full-length Chordin or CR1 proteins and immunoprecipitated with protein A Sepharose. As can be seen in Fig. 4C Taken together, the results show that CR1 is approximately 5−10 times less active than full-length Chordin in biological assays, a finding that correlates with the lower affinity of the CR1/BMP interaction in biochemical assays. Since the CR1 construct mimics one of the digestion products of the Xolloid metalloprotease (Piccolo et al., 1997; Scott et al., 1999), the results suggest that Xolloid digestion may regulate Chordin/BMP complexes by releasing proteolytic fragments with decreased anti-BMP activity, as indicated schematically in Fig. 4D Type IIA procollagen has dorsalizing activity CR repeats of the type present in Chordin are found in many ECM proteins. To test whether our findings with Chordin could serve as a more general model for understanding the interaction of TGFβ superfamily members with the ECM, we examined the function of procollagen IIA. Studies by Sandell and colleagues have shown that procollagen II is synthesized in two alternatively spliced forms, type IIA and IIB. Type IIA contains a 69 amino acid CR domain in its NH2-propetide that is specifically spliced out in the IIB form expressed in mature chondrocytes (Ryan and Sandell, 1990; Sandell et al., 1991, 1994; Ng et al., 1993). From a developmental standpoint procollagen IIA is of particular interest, since it has long been used as a dorsal marker in early Xenopus development (Su et al., 1991). As shown in Fig. 5
To determine whether the procollagen CR (cloned as a 115 amino acid fragment) had binding activity, the co-immunoprecipitation assay described above was utilized. We found that procollagen IIA CR bound BMP4 about as well as CR2 (Fig. 6A
These observations raise the possibility that CR domains could provide binding modules for a variety of members of the TGFβ superfamily of growth factors. As shown in Fig. 6C When synthetic mRNA for the procollagen IIA CR (coll-CR) domain was injected into Xenopus embryos, we failed to detect any phenotypes over a wide range of concentrations (Fig. 7E
To explore whether other CR-containing proteins might have similar biological activity in Xenopus, we injected full-length C.elegans CAA94886 synthetic mRNA (800 pg) encoding a protein containing 5 CRs (Wilson et al., 1994), which caused formation of secondary axes of the type induced by chordin or procollagen IIA (Fig. 7H DISCUSSION The experiments presented here provide evidence that the biological activity of Chordin resides in the cysteine-rich repeats (CRs), particularly in CR1 and CR3. These repeats can dorsalize embryos and VMZ explants but, at equimolar levels, CR1 and CR3 have 5−10 times less activity than full-length Chordin. CR1 and CR3 repeats bind BMP4 with an affinity (KD 2.4 and 2.0 nM, respectively) that is 7- to 8-fold lower than that of full-length Chordin (KD=0.3 nM) (Piccolo et al., 1996). CR2 and CR4 have almost no biological activity and bind BMP4 only very weakly (Fig. 2 The Chordin/BMP pathway is regulated by the zinc metalloprotease Xolloid (Piccolo et al., 1997), a homologue of Drosophila Tolloid that regulates the activity of Sog (Marqués et al., 1997). Our observations begin to provide a molecular explanation for how Xolloid may regulate Chordin. Xolloid cleaves Chordin at two sites, which had been roughly mapped close downstream of CR1 and CR3 (Piccolo et al., 1997). Recently, the cleavage sites have been sequenced and found to correspond to conserved aspartic residues (Scott et al., 1999). The CR1 protein used in this study is very similar in length (only 8 amino acids shorter) to the fragment generated by metalloprotease cleavage in the N-terminal site of Chordin. We have shown that CR1 binds BMP4 with a lower affinity (8-fold lower), is less efficient in competing BMP4 binding to BMPR (10 times lower), and has less biological activity (5- to 10-fold lower) than full-length Chordin. It is conceivable that the Xolloid protease inactivates Chordin by the generation of smaller fragments that can still bind BMP and perhaps transport it. However, each of these binding modules alone would not have high enough affinity to compete (Fig. 4D In Drosophila, elegant studies have shown that Sog not only inhibits Dpp signalling but is also able to enhance it at a distance (Zusman et al., 1988; Ferguson and Anderson, 1992; Ashe and Levine, 1999). This enhancement of BMP signals requires Sog diffusion (presumably carrying bound Dpp or Screw) and the activity of the Tolloid protease (Ashe and Levine, 1999). It has been suggested that cleavage products of Sog, or Sog fragments complexed with Dpp, could augment the binding of Dpp/Screw to its receptors (Bier, 1999). None of our Chordin constructs, including a series of carboxy-terminal protein truncations not described here, displayed ventralizing effects as would be expected if there were increased binding to receptors. Rather, the observation that Chordin fragments are either weakly dorsalizing or inactive in Xenopus assays tends to support the initial proposal by Holley et al. (1996). In this proposal, the diffusion of Chd/Sog complexed with BMP/Dpp contributes to the formation of morphogen gradients in which maximal levels of signalling are achieved by cleavage of the inhibitor and release of the active BMP signal. The CR domains of Chordin define a novel protein module for BMP binding. The cysteine-rich (CR) domains present in the NH2-propeptide of Xenopus type IIA procollagen bind BMP4 with an affinity comparable to that of CR2, and this binding can be competed by BMP2 and TGFβ1 (Fig. 6A,B CRs are present in many ECM proteins such as fibrillar procollagens (I, II, III and V), von Willebrand factor, thrombospondin 1 and 2 (Bornstein, 1992), Drosophila peroxidasin (Nelson et al., 1994), the secreted proteins Nel, Nel-like-1 and Nel-like-2, which contain four CR repeats and six EGF repeats each (Matsuhashi et al., 1995; Watanabe et al., 1996) and the aforementioned C. elegans protein CAA94886 containing five CR repeats. Since these CR repeats vary widely in sequence, they might bind a wide range of TGFβ superfamily members. This is in fact likely in view of the observations that, whereas Chordin CR1 interacts with BMPs but not TGFβ1, procollagen IIA CR can interact both with BMP and TGFβ1 (Zhu et al., 1999; this study). It is attractive to propose that CRs, which are abundantly represented in the ECM of many tissues, may function as a sink for TGFβ superfamily members. These bound growth factors could be subsequently liberated by specific proteases, such as members of the Tolloid/BMP1 family, when required for tissue differentiation and homeostasis (Piccolo et al., 1997; Marqués et al., 1997; Goodman et al., 1998; Imamura et al., 1998). The dorsalizing activity of Xenopus type IIA procollagen could be of functional importance during early development. This molecule is one of the classical markers used to identify dorsal regions during vertebrate development. In the frog embryo, it is strongly expressed in the notochord and somites at neurulation and tailbud stages (Su et al., 1991). In zebrafish, collagen II expression is very strong in posterior notochord, floor plate and hypochord, and its downregulation in the notochord is finely spatiotemporally regulated in a number of developmental mutations (Yan et al., 1995; Stemple et al., 1996). In mouse, procollagen II is strongly expressed in the notochord and sclerotomes (Cheah et al., 1991). A mouse mutant lacking the carboxy-terminus of collagen II shows a failure of the notochord to degenerate and form the nucleus of the intervertebral discs (Aszódi et al., 1998). In future, mouse mutations targeting specifically the CR of procollagen II will be of great interest. Because of its anti-BMP activity and expression pattern, type IIA procollagen is a good candidate to cooperate in the maintenance of dorsal values, particularly during later stages of development in which chordin mRNA levels decrease (Fig. 5 In conclusion, the large body of genetic data concerning the interactions between the Chordin/Sog, Dpp/BMP and Xolloid/Tolloid gene products has led to a useful paradigm of how cell signalling is modulated in the extracellular space. The present demonstration that this regulation works in part through binding to cysteine-rich domains in Chordin may provide mechanistic insights into how other ECM proteins with CR domains might function. Acknowledgments We are indebted to Dr Francesco Ramirez for providing the full-length Xenopus procollagen IIA cDNA, Dr Yuji Kohara for the C. elegans EST, to Genetics Institute for BMP2 and BMP4, and to Dr K. Masuhara for monoclonal anti-BMP4 antibody. We thank members of our laboratory for comments on the manuscript. This work was supported by grant NIH R37 HD21502−13. J. L. was supported by a Pew Fellowship and E. M. D. R. is an investigator of the Howard Hughes Medical Institute. REFERENCES
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Annu Rev Cell Dev Biol. 1997; 13():611-67.
[Annu Rev Cell Dev Biol. 1997]Nature. 1996 Mar 7; 380(6569):37-40.
[Nature. 1996]Cell. 1996 Aug 23; 86(4):589-98.
[Cell. 1996]Nature. 1997 Jun 26; 387(6636):862-3.
[Nature. 1997]Development. 1997 Nov; 124(22):4457-66.
[Development. 1997]Genes Dev. 1996 Oct 1; 10(19):2452-61.
[Genes Dev. 1996]Cell. 1995 Jan 13; 80(1):19-20.
[Cell. 1995]Nature. 1995 Jul 20; 376(6537):249-53.
[Nature. 1995]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Development. 1992 Mar; 114(3):583-97.
[Development. 1992]Nature. 1999 Apr 1; 398(6726):427-31.
[Nature. 1999]Cell. 1997 Oct 31; 91(3):417-26.
[Cell. 1997]Development. 1999 Jun; 126(14):3119-30.
[Development. 1999]Genes Dev. 1994 Nov 1; 8(21):2602-16.
[Genes Dev. 1994]Cell. 1994 Dec 2; 79(5):779-90.
[Cell. 1994]J Cell Biol. 1999 Mar 8; 144(5):1069-80.
[J Cell Biol. 1999]Genomics. 1998 Sep 1; 52(2):236-9.
[Genomics. 1998]Science. 1995 May 12; 268(5212):836-44.
[Science. 1995]J Biol Chem. 1990 Jun 25; 265(18):10334-9.
[J Biol Chem. 1990]J Cell Biol. 1991 Oct; 115(2):565-75.
[J Cell Biol. 1991]J Cell Biol. 1991 Oct; 115(2):565-75.
[J Cell Biol. 1991]Cell. 1994 Dec 2; 79(5):779-90.
[Cell. 1994]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Cell. 1996 Aug 23; 86(4):589-98.
[Cell. 1996]Cell. 1996 Aug 23; 86(4):589-98.
[Cell. 1996]Cell. 1994 Dec 2; 79(5):779-90.
[Cell. 1994]Cell. 1996 Aug 23; 86(4):589-98.
[Cell. 1996]Dev Biol. 1996 Feb 25; 174(1):174-8.
[Dev Biol. 1996]Nature. 1995 Jul 27; 376(6538):333-6.
[Nature. 1995]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Dev Biol. 1999 Sep 15; 213(2):283-300.
[Dev Biol. 1999]Cell. 1994 Dec 2; 79(5):779-90.
[Cell. 1994]Cell. 1996 Aug 23; 86(4):589-98.
[Cell. 1996]Cell. 1996 Aug 23; 86(4):589-98.
[Cell. 1996]Cell. 1996 Aug 23; 86(4):589-98.
[Cell. 1996]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Dev Biol. 1999 Sep 15; 213(2):283-300.
[Dev Biol. 1999]J Biol Chem. 1990 Jun 25; 265(18):10334-9.
[J Biol Chem. 1990]J Cell Biol. 1991 Sep; 114(6):1307-19.
[J Cell Biol. 1991]Dev Dyn. 1994 Feb; 199(2):129-40.
[Dev Dyn. 1994]Dev Biol. 1993 Oct; 159(2):403-17.
[Dev Biol. 1993]J Cell Biol. 1991 Oct; 115(2):565-75.
[J Cell Biol. 1991]J Cell Biol. 1999 Mar 8; 144(5):1069-80.
[J Cell Biol. 1999]Dev Dyn. 1995 Jun; 203(2):212-22.
[Dev Dyn. 1995]FASEB J. 1992 Nov; 6(14):3290-9.
[FASEB J. 1992]EMBO J. 1994 Aug 1; 13(15):3438-47.
[EMBO J. 1994]Nature. 1994 Mar 3; 368(6466):32-8.
[Nature. 1994]Nature. 1994 Mar 3; 368(6466):32-8.
[Nature. 1994]Cell. 1996 Aug 23; 86(4):589-98.
[Cell. 1996]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Cell. 1997 Oct 31; 91(3):417-26.
[Cell. 1997]Dev Biol. 1999 Sep 15; 213(2):283-300.
[Dev Biol. 1999]Cell. 1996 Aug 23; 86(4):589-98.
[Cell. 1996]Development. 1992 Mar; 114(3):583-97.
[Development. 1992]Nature. 1999 Apr 1; 398(6726):427-31.
[Nature. 1999]Nature. 1999 Apr 1; 398(6726):375-6.
[Nature. 1999]Cell. 1996 Aug 23; 86(4):607-17.
[Cell. 1996]J Cell Biol. 1999 Mar 8; 144(5):1069-80.
[J Cell Biol. 1999]J Biol Chem. 1987 Oct 5; 262(28):13457-63.
[J Biol Chem. 1987]FASEB J. 1992 Nov; 6(14):3290-9.
[FASEB J. 1992]EMBO J. 1994 Aug 1; 13(15):3438-47.
[EMBO J. 1994]Dev Dyn. 1995 Jun; 203(2):212-22.
[Dev Dyn. 1995]Genomics. 1996 Dec 15; 38(3):273-6.
[Genomics. 1996]J Cell Biol. 1999 Mar 8; 144(5):1069-80.
[J Cell Biol. 1999]J Cell Biol. 1991 Oct; 115(2):565-75.
[J Cell Biol. 1991]Dev Dyn. 1995 Jul; 203(3):363-76.
[Dev Dyn. 1995]Development. 1996 Dec; 123():117-28.
[Development. 1996]Development. 1991 Apr; 111(4):945-53.
[Development. 1991]J Cell Biol. 1998 Nov 30; 143(5):1399-412.
[J Cell Biol. 1998]Cell. 1996 Aug 23; 86(4):589-98.
[Cell. 1996]